Income before deduction of interest, taxes and amortization: Enveric Biosciences, Inc. (ENVB)

Enveric Biosciences (ENVB) development relies on the creation of small psychedelic molecules, ignoring macroeconomic fluctuations. The intrinsic value is based on the Psybrary AI platform, which creates non-hallucinogenic drugs with inelastic demand. The EBITDA growth trajectory demonstrates a dependence on biological data and trial timelines, while the indicator is maintained at 0.00, determining the real liquidity of the business.

This indicator calculates operating profit before depreciation and amortization, measuring a business's ability to generate cash flow from core operations excluding debt obligations and taxes. For Enveric Biosciences (ENVB), the annual EBITDA reflects a critical R&D cash burn rate in the absence of revenue, signaling to investors the biotech startup's dependence on external financing.